汤臣倍健(300146)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300146 汤臣倍健

交易中 03-28 11:01:09

{"stockData":{"symbol":"300146","market":"SZ","secType":"STK","nameCN":"汤臣倍健","latestPrice":20.41,"timestamp":1679972469000,"preClose":20.27,"halted":0,"volume":4420249,"delay":0,"floatShares":1130000000,"shares":1700000000,"eps":0.5985,"marketStatus":"交易中","marketStatusCode":2,"change":0.14,"latestTime":"03-28 11:01:09","open":20.3,"high":20.6,"low":20.18,"amount":90245700,"amplitude":0.0207,"askPrice":20.41,"askSize":161,"bidPrice":20.4,"bidSize":33,"shortable":0,"etf":0,"ttmEps":0.5985,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1679974200000},"adr":0,"adjPreClose":20.27,"symbolType":"stock","highLimit":22.3,"lowLimit":18.24,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1700462263,"pbRate":3.22,"roa":"--","roe":"13.46%","epsLYR":0.82,"committee":0.022091,"marketValue":34706000000,"floatMarketCap":23055000000,"peRate":34.101921,"changeRate":0.0069,"turnoverRate":0.0039,"status":0},"requestUrl":"/m/hq/s/300146","defaultTab":"news","newsList":[{"id":"2321910455","title":"汤臣倍健（300146）3月22日主力资金净卖出604.35万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2321910455","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2321910455?lang=zh_CN&edition=full","pubTime":"2023-03-23 09:02","pubTimestamp":1679533354,"startTime":"0","endTime":"0","summary":"截至2023年3月22日收盘，汤臣倍健报收于20.3元，下跌2.07%，换手率0.63%，成交量7.09万手，成交额1.45亿元。近5日资金流向一览见下表：汤臣倍健融资融券信息显示，融资方面，当日融资买入1470.6万元，融资偿还1084.89万元，融资净买入385.71万元。汤臣倍健主营业务：膳食营养补充剂的研发、生产和销售。。根据近五年财报数据，证券之星估值分析工具显示，汤臣倍健行业内竞争力的护城河良好，盈利能力良好，营收成长性一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032300011652.shtml","is_publish_highlight":false},{"id":"2321893697","title":"汤臣倍健：公司线上渠道销售采取直营和经销模式，有授权经销商进行电商渠道的运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2321893697","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2321893697?lang=zh_CN&edition=full","pubTime":"2023-03-22 14:20","pubTimestamp":1679466032,"startTime":"0","endTime":"0","summary":"公司线上渠道销售采取直营和经销模式，有授权经销商进行电商渠道的运营。从销量下降销售额仍微涨以及毛利率上升可以证实经营质量提升应该不假。预计2023年公司销售费用率较2022年略微下降。中康CMH零售市场数据显示，2022年中国药店膳食营养补充剂整体增速为-1.7%，汤臣倍健增速为3.2%，公司在药店渠道所处行业的份额稳中有升。线上渠道准入门槛较低品牌众多，竞争相对激烈。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032200018125.shtml","is_publish_highlight":false},{"id":"2321047806","title":"【机构调研记录】北信瑞丰调研汤臣倍健","url":"https://stock-news.laohu8.com/highlight/detail?id=2321047806","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2321047806?lang=zh_CN&edition=full","pubTime":"2023-03-22 08:02","pubTimestamp":1679443342,"startTime":"0","endTime":"0","summary":"北信瑞丰成立于2014年，截至目前，资产规模(全部)28.45亿元，排名159/197；资产规模(非货币)13.1亿元，排名157/197；管理基金数21只，排名125/197；旗下基金经理8人，排名117/197。旗下最近一年表现最佳的基金产品为北信瑞丰外延增长，最新单位净值为2.0，近一年增长32.16%。以上内容由证券之星根据公开信息整理，与本站立场无关。证券之星力求但不保证该信息全部或者部分内容的的准确性、完整性、有效性、及时性等，如存在问题请联系我们。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032200009973.shtml","is_publish_highlight":false},{"id":"2321756604","title":"【机构调研记录】汇丰晋信基金调研汤臣倍健、欧普照明","url":"https://stock-news.laohu8.com/highlight/detail?id=2321756604","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2321756604?lang=zh_CN&edition=full","pubTime":"2023-03-22 08:02","pubTimestamp":1679443324,"startTime":"0","endTime":"0","summary":"汇丰晋信基金成立于2005年，截至目前，资产规模(全部)478.3亿元，排名81/197；资产规模(非货币)382.67亿元，排名78/197；管理基金数54只，排名84/197；旗下基金经理14人，排名84/197。旗下最近一年表现最佳的基金产品为汇丰晋信珠三角区域发展混合，最新单位净值为2.02，近一年增长20.24%。以上内容由证券之星根据公开信息整理，与本站立场无关。证券之星力求但不保证该信息全部或者部分内容的的准确性、完整性、有效性、及时性等，如存在问题请联系我们。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032200009952.shtml","is_publish_highlight":false},{"id":"2321047646","title":"【机构调研记录】交银施罗德基金韩威俊，郭斐调研汤臣倍健，宇瞳光学","url":"https://stock-news.laohu8.com/highlight/detail?id=2321047646","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2321047646?lang=zh_CN&edition=full","pubTime":"2023-03-22 08:02","pubTimestamp":1679443324,"startTime":"0","endTime":"0","summary":"交银施罗德基金成立于2005年，截至目前，资产规模(全部)5293.53亿元，排名18/197；资产规模(非货币)3339.16亿元，排名15/197；管理基金数200只，排名25/197；旗下基金经理34人，排名27/197。旗下最近一年表现最佳的基金产品为交银国企改革灵活配置混合A，最新单位净值为1.92，近一年增长15.44%。以上内容由证券之星根据公开信息整理，与本站立场无关。证券之星力求但不保证该信息全部或者部分内容的的准确性、完整性、有效性、及时性等，如存在问题请联系我们。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032200009953.shtml","is_publish_highlight":false},{"id":"2321604223","title":"【机构调研记录】申万菱信基金调研汤臣倍健、欧普照明等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2321604223","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2321604223?lang=zh_CN&edition=full","pubTime":"2023-03-22 08:01","pubTimestamp":1679443313,"startTime":"0","endTime":"0","summary":"申万菱信基金成立于2004年，截至目前，资产规模(全部)746.93亿元，排名64/197；资产规模(非货币)713.9亿元，排名54/197；管理基金数137只，排名41/197；旗下基金经理24人，排名49/197。旗下最近一年表现最佳的基金产品为申万菱信消费增长混合A，最新单位净值为1.52，近一年增长9.34%。以上内容由证券之星根据公开信息整理，与本站立场无关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032200009940.shtml","is_publish_highlight":false},{"id":"2321760421","title":"【私募调研记录】银叶投资调研汤臣倍健、天山铝业","url":"https://stock-news.laohu8.com/highlight/detail?id=2321760421","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2321760421?lang=zh_CN&edition=full","pubTime":"2023-03-22 08:01","pubTimestamp":1679443279,"startTime":"0","endTime":"0","summary":"依靠长期深耕中国资本市场积累的专业优势，银叶已经形成覆盖固定收益、宏观对冲、权益投资、量化及衍生品策略等多元化的投资体系。公司是中国证券投资基金业协会首批会员、中国银行间市场交易商协会会员和人民币利率互换市场和远期利率市场成员。本次调研的上市公司平均证券之星综合指标3.5星，平均市盈率21.33。以上内容由证券之星根据公开信息整理，与本站立场无关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2023032200009906.shtml","is_publish_highlight":false},{"id":"2321212604","title":"【私募调研记录】诚盛投资调研汤臣倍健","url":"https://stock-news.laohu8.com/highlight/detail?id=2321212604","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2321212604?lang=zh_CN&edition=full","pubTime":"2023-03-22 08:01","pubTimestamp":1679443275,"startTime":"0","endTime":"0","summary":"诚盛投资本着\"诚信、稳健、共赢\"的宗旨，致力于与客户、员工、股东共同分享证券市场的发展机遇。证券之星点评：诚盛投资在2021年证券之星私募顶投榜中排名第43位，其管理规模50~100亿，拥有完永东等知名基金经理。本次调研的上市公司平均证券之星综合指标3.5星，平均市盈率25.43。以上内容由证券之星根据公开信息整理，与本站立场无关。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2023032200009901.shtml","is_publish_highlight":false},{"id":"2321069660","title":"汤臣倍健（300146）3月20日主力资金净卖出5024.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2321069660","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2321069660?lang=zh_CN&edition=full","pubTime":"2023-03-21 09:13","pubTimestamp":1679361227,"startTime":"0","endTime":"0","summary":"截至2023年3月20日收盘，汤臣倍健报收于20.0元，下跌9.3%，换手率2.75%，成交量31.03万手，成交额6.27亿元。近5日资金流向一览见下表：汤臣倍健融资融券信息显示，融资方面，当日融资买入7539.77万元，融资偿还3531.29万元，融资净买入4008.48万元。汤臣倍健主营业务：膳食营养补充剂的研发、生产和销售。。根据近五年财报数据，证券之星估值分析工具显示，汤臣倍健行业内竞争力的护城河良好，盈利能力良好，营收成长性一般。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032100013156.shtml","is_publish_highlight":false},{"id":"2320508208","title":"历史罕见！汤臣倍健董事长发声：业绩“不可接受”，股价大跌！","url":"https://stock-news.laohu8.com/highlight/detail?id=2320508208","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2320508208?lang=zh_CN&edition=full","pubTime":"2023-03-20 12:27","pubTimestamp":1679286420,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　3月20日上午，食品饮料表现不振，多只个股持续走低。　　汤臣倍健早间开盘不利，盘中股价持续下挫，截至午间收盘，汤臣倍健股价来到19.91元/股，跌9.71%。　　3月17日晚间，汤臣倍健发布2022年年报显示，其当年营业收入为78.61亿元，同比增长5.79%；归母净利润13.86亿元，同比下降20.99%，呈“增收不增利”的局面。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2023-03-20/doc-imymnxfy3379339.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2023-03-20/doc-imymnxfy3379339.shtml","is_publish_highlight":false},{"id":"2320590315","title":"汤臣倍健(300146)2月28日股东户数5.1万户，较上期减少7.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2320590315","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2320590315?lang=zh_CN&edition=full","pubTime":"2023-03-18 16:59","pubTimestamp":1679129997,"startTime":"0","endTime":"0","summary":"近日汤臣倍健披露，截至2023年2月28日公司股东户数为5.1万户，较12月31日减少3958.0户，减幅为7.21%。在食品加工行业个股中，汤臣倍健股东户数高于行业平均水平，截至2月28日，食品加工行业平均股东户数为3.95万户。从股价来看，2022年12月31日至2023年2月28日，汤臣倍健区间涨幅为0.61%，在此期间股东户数减少3958户，减幅为7.21%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023031800013454.shtml","is_publish_highlight":false},{"id":"2320137497","title":"汤臣倍健(300146.SZ)发布2022年度业绩，净利润13.86亿元，下降20.99%，拟10股派1.8元","url":"https://stock-news.laohu8.com/highlight/detail?id=2320137497","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2320137497?lang=zh_CN&edition=full","pubTime":"2023-03-17 19:56","pubTimestamp":1679054202,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汤臣倍健 发布2022年年度报告，该公司营业收入为78.61亿元，同比增长5.79%。归属于上市公司股东的净利润为13.86亿元，同比减少20.99%。境内业务方面：①主品牌“汤臣倍健”实现收入44.45亿元，与去年基本持平;关节护理品牌“健力多”实现收入12.10亿元，同比下降14.09%;“Life-Space”国内产品实现收入3.03亿元，同比增长64.42%。此外，拟向全体股东每10股派发现金红利1.8元(含税)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/894110.html","is_publish_highlight":false},{"id":"2320337609","title":"汤臣倍健最新公告：2022年净利润同比下降20.99% 拟10派1.8元","url":"https://stock-news.laohu8.com/highlight/detail?id=2320337609","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2320337609?lang=zh_CN&edition=full","pubTime":"2023-03-17 19:00","pubTimestamp":1679050856,"startTime":"0","endTime":"0","summary":"汤臣倍健公告，2022年净利润13.86亿元，同比下降20.99%，拟10派1.8元。截至2023年3月17日收盘，汤臣倍健报收于22.05元，上涨0.64%，换手率0.67%，成交量7.62万手，成交额1.69亿元。根据近五年财报数据，证券之星估值分析工具显示，汤臣倍健行业内竞争力的护城河良好，盈利能力良好，营收成长性一般。重仓汤臣倍健的前十大基金见下表：其中持有数量最多的基金为交银品质增长一年混合A，目前规模为51.57亿元，最新净值0.9995，较上一交易日下跌0.25%，近一年上涨15.4%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023031700031097.shtml","is_publish_highlight":false},{"id":"2319756170","title":"汤臣倍健：公司持续开展抗衰老及精准营养等前瞻性基础研究，基于研究成果进行相关产品研发和功能试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2319756170","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2319756170?lang=zh_CN&edition=full","pubTime":"2023-03-14 16:14","pubTimestamp":1678781655,"startTime":"0","endTime":"0","summary":"汤臣倍健03月14日在投资者关系平台上答复了投资者关心的问题。公司持续开展抗衰老及精准营养等前瞻性基础研究，基于研究成果进行相关产品研发和功能试验。汤臣倍健主营业务：膳食营养补充剂的研发、生产和销售。以上内容由证券之星根据公开信息整理，与本站立场无关。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023031400016977.shtml","is_publish_highlight":false},{"id":"2316956244","title":"猛砸销售费用，汤臣倍健把2022年净利润砸出“坑”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2316956244","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2316956244?lang=zh_CN&edition=full","pubTime":"2023-03-02 22:29","pubTimestamp":1677767340,"startTime":"0","endTime":"0","summary":"　　作为行业翘楚，汤臣倍健在2020年和2021年交出了双增长的财报，股价也得到大幅提振。　　不过，进入2022年，该高昂的形势终究没有持续下去。　　据公司年度业绩预告显示，汤臣倍健预计2022年归母净利润在12.28亿元-15.79亿元，同比下降10%-30%；扣非后归母净利润在11.18亿元-15.39亿元之间，同比下降0.11%-23.53%。　　此前，汤臣倍健也在证券平台表示，预计2022年公司销售费用率维持在较高水平。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2023-03-02/doc-imyinyii7815763.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2023-03-02/doc-imyinyii7815763.shtml","is_publish_highlight":false},{"id":"2316670531","title":"汤臣倍健：上述主要系公司购买的大额存单和理财产品到期所致","url":"https://stock-news.laohu8.com/highlight/detail?id=2316670531","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2316670531?lang=zh_CN&edition=full","pubTime":"2023-03-02 10:00","pubTimestamp":1677722445,"startTime":"0","endTime":"0","summary":"汤臣倍健03月02日在投资者关系平台上答复了投资者关心的问题。上述主要系公司购买的大额存单和理财产品到期所致，感谢关注。汤臣倍健主营业务：膳食营养补充剂的研发、生产和销售。以上内容由证券之星根据公开信息整理，与本站立场无关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023030200003516.shtml","is_publish_highlight":false},{"id":"2312416764","title":"2月20日汤臣倍健涨5.12%，交银品质增长一年混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2312416764","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2312416764?lang=zh_CN&edition=full","pubTime":"2023-02-20 16:24","pubTimestamp":1676881497,"startTime":"0","endTime":"0","summary":"2月20日汤臣倍健涨5.12%，收盘报23.2元，换手率1.59%，成交量17.94万手，成交额4.11亿元。根据2022年报公募基金重仓股数据，重仓该股的公募基金共19家，其中持有数量最多的公募基金为交银品质增长一年混合A。交银品质增长一年混合A的前十大重仓股如下：以上内容由证券之星根据公开信息整理，与本站立场无关。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023022000009543.shtml","is_publish_highlight":false},{"id":"2311471671","title":"汤臣倍健：目前公司暂无相关产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2311471671","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2311471671?lang=zh_CN&edition=full","pubTime":"2023-02-15 10:39","pubTimestamp":1676428748,"startTime":"0","endTime":"0","summary":"汤臣倍健董秘：投资者您好，公司“科学营养”战略实施将高度聚集科技核心竞争力打造上，具体实施体现在三个方面：1.自有专利原料和配方研发；2.新功能及重功能产品研发和注册；3.前瞻性基础研究成果发布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023021500003422.shtml","is_publish_highlight":false}],"profile":{"ret":0,"listingDate":"2010-12-15","address":"广东省珠海市金湾区三灶科技工业园星汉路19号","stockEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":-0.1015},{"period":"3month","weight":-0.1175},{"period":"6month","weight":0.1563},{"period":"1year","weight":0.0005},{"period":"ytd","weight":-0.1117}],"companyName":"汤臣倍健股份有限公司","boardCode":"AI0014","perCapita":"22162股","boardName":"食品制造业","registeredCapital":"170046万元","compareEarnings":[{"period":"1week","weight":0.0051},{"period":"1month","weight":-0.0048},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.0678},{"period":"1year","weight":0.0122},{"period":"ytd","weight":0.0525}],"survey":"　　汤臣倍健股份有限公司是膳食营养补充剂的研发、生产和销售。主要产品涵盖了片剂、粉剂、胶囊。公司拥有144个保健食品批准证书及90款保健食品备案凭证。2018年10月，国家工业和信息化部正式公布了第三批“绿色工厂”名单，汤臣倍健透明工厂进入名单。","serverTime":1679972471869,"listedPrice":110,"stockholders":"50969人(较上一季度减少7.21%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.12.1","shortVersion":"4.12.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汤臣倍健(300146)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汤臣倍健(300146)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汤臣倍健,300146,汤臣倍健股票,汤臣倍健股票老虎,汤臣倍健股票老虎国际,汤臣倍健行情,汤臣倍健股票行情,汤臣倍健股价,汤臣倍健股市,汤臣倍健股票价格,汤臣倍健股票交易,汤臣倍健股票购买,汤臣倍健股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汤臣倍健(300146)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汤臣倍健(300146)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}